ADMA Adma Biologics Inc

Price (delayed)

$1.915

Market cap

$376.01M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$0.48

Enterprise value

$445.59M

ADMA Biologics is an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing and developing specialty plasma-derived biologics for the treatment of immunodeficient patients at risk for infection and others at ...

Highlights
The gross profit has soared by 146% YoY
ADMA's gross margin has soared by 124% YoY
ADMA's quick ratio is down by 18% YoY but it is up by 15% QoQ
The equity has increased by 13% year-on-year but it has declined by 10% since the previous quarter
The company's debt rose by 48% YoY and by 46% QoQ
The company's net income fell by 9% QoQ and by 4.5% YoY

Key stats

What are the main financial stats of ADMA
Market
Shares outstanding
196.35M
Market cap
$376.01M
Enterprise value
$445.59M
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
2.96
Price to sales (P/S)
3.99
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
4.74
Earnings
Revenue
$94M
EBIT
-$65.03M
EBITDA
-$59.17M
Free cash flow
-$118.94M
Per share
EPS
-$0.48
Free cash flow per share
-$0.61
Book value per share
$0.65
Revenue per share
$0.48
TBVPS
$1.55
Balance sheet
Total assets
$308.03M
Total liabilities
$181.1M
Debt
$139.08M
Equity
$126.93M
Working capital
$208.23M
Liquidity
Debt to equity
1.1
Current ratio
7.6
Quick ratio
3.01
Net debt/EBITDA
-1.18
Margins
EBITDA margin
-62.9%
Gross margin
7%
Net margin
-83.3%
Operating margin
-61.7%
Efficiency
Return on assets
-29.7%
Return on equity
-64.9%
Return on invested capital
-22.7%
Return on capital employed
-23.5%
Return on sales
-69.2%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

ADMA stock price

How has the Adma Biologics stock price performed over time
Intraday
-7.49%
1 week
-12.95%
1 month
4.08%
1 year
16.06%
YTD
35.82%
QTD
4.64%

Financial performance

How have Adma Biologics's revenue and profit performed over time
Revenue
$94M
Gross profit
$6.56M
Operating income
-$58.02M
Net income
-$78.28M
Gross margin
7%
Net margin
-83.3%
The gross profit has soared by 146% YoY
ADMA's gross margin has soared by 124% YoY
ADMA's revenue has surged by 96% year-on-year and by 16% since the previous quarter
Adma Biologics's operating margin has surged by 53% YoY and by 14% QoQ

Growth

What is Adma Biologics's growth rate over time

Valuation

What is Adma Biologics stock price valuation
P/E
N/A
P/B
2.96
P/S
3.99
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
4.74
The EPS has grown by 38% year-on-year and by 6% since the previous quarter
The price to book (P/B) is 60% higher than the last 4 quarters average of 2.0 but 33% lower than the 5-year quarterly average of 4.8
The equity has increased by 13% year-on-year but it has declined by 10% since the previous quarter
ADMA's revenue has surged by 96% year-on-year and by 16% since the previous quarter
ADMA's price to sales (P/S) is 44% higher than its last 4 quarters average of 3.0 but 33% lower than its 5-year quarterly average of 6.4

Efficiency

How efficient is Adma Biologics business performance
The return on sales has grown by 47% year-on-year and by 4.4% since the previous quarter
ADMA's ROE is up by 24% YoY but it is down by 6% QoQ
The company's return on invested capital rose by 22% YoY
The company's return on assets rose by 18% YoY but it fell by 2.1% QoQ

Dividends

What is ADMA's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for ADMA.

Financial health

How did Adma Biologics financials performed over time
Adma Biologics's total assets is 70% more than its total liabilities
Adma Biologics's total liabilities has increased by 47% YoY and by 34% QoQ
Adma Biologics's total assets has increased by 31% YoY and by 12% from the previous quarter
The company's debt is 10% higher than its equity
Adma Biologics's debt to equity has surged by 62% QoQ and by 33% YoY
The company's debt rose by 48% YoY and by 46% QoQ

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.